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ABSTRACT
Introduction: Dyspnoea is a common
symptom of chronic obstructive pulmonary
disease (COPD) that has a significant direct
impact on patients’ respiratory health status
and contributes substantially to the economic
burden of the disease. The objective of this
study was to report on the prevalence of
dyspnoea and its cost impact among patients
with COPD in five European countries (France,
Germany, Italy, Spain and the UK).
Methods: A population-based cross-sectional
survey (Respiratory Disease-Specific Programme,
Adelphi Real World) was conducted among 2531
patientswithCOPDand their treatingphysicians.
Information was collected on demographic and
clinical characteristics, dyspnoea [modified
Medical Research Council (mMRC) scale], health
status [COPD Assessment Test (CAT), EuroQol
(EQ-5D-3L)], sleep [Jenkins Sleep Evaluation
Questionnaire (JSEQ)], and healthcare resource
use including moderate-to-severe COPD
exacerbations, physician visits, COPD
medications, and other COPD-related resources.
The humanistic and economic burden was
derived from two cohorts based on their level of
dyspnoea (mMRC\2 vs. mMRC C2) who were
matched by propensity scores to balance their
demographic and disease burden characteristics.
Results: Moderate-to-severe dyspnoea (mMRC
C2) was highly prevalent across all countries,
ranging from 39.5% in France to 60.2% in the
UK. Overall in the unmatched cohorts, mMRC
C2 (n = 1199) was associated with more
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comorbidities and more frequent exacerbations
([2/year) compared to patients with mMRC\2
(n = 1332). Descriptive analysis indicated that
the patient cohort with worse dyspnoea had
poorer health status (CAT: 25.1 vs. 16.2;
P\0.0001), poorer sleep (JSEQ: 7.1 vs. 3.8;
P\0.0001), and poorer quality of life
(EQ-5D-3L: 0.66 vs. 0.88; P\0.0001). These
findings were replicated in each of the five EU
countries. In the propensity score-matched
population balanced for non-dyspnoeic severity
parameters, patients with worse dyspnoea had
significantly higher annual costs for COPD
management (€4372 vs. €2031, P\0.0001).
Conclusion: Moderate-to-severe dyspnoea is
highly prevalent in patients with COPD across
the five European countries studied. It is
associated with a significant disease burden
and more than doubles the economic burden
on health care systems.
Funding: GlaxoSmithKline (Study number
HO-15-15223).
Keywords: Chronic obstructive pulmonary
disease (COPD); Costs; Dyspnoea; Prevalence;
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD)
is characterized by persistent, usually progressive,
airflow limitation [1]. COPD is a major cause of
chronic morbidity and mortality, and presents a
significant health challenge to payers across the
world [2]. Despite being a preventable and
treatable condition, COPD remains the third
leading cause of death in the world [3].
Dyspnoea, commonly known as
breathlessness, is the most common symptom
of COPD [4]. An increase in the level of dyspnoea
is associated with an increase in fatigue and
disability [5]. Dyspnoea has also been shown to
be associated with a decrease in health-related
quality of life [6]. However, cultural dimensions
such as differences in language, race, ethnicity,
and gender can influence the interpretation,
quality, and intensity of reported dyspnoea [7].
Whilst there is evidence showing that higher
levels of dyspnoea are associated with an
increased risk of a COPD exacerbation and
mortality, there is limited evidence reporting
the healthcare resource use (HCRU) among
patients with differing levels of dyspnoea for
the majority of countries [8, 9].
The objective of this study was to report the
prevalence of moderate-to-severe dyspnoea and
explore its humanistic and economic impact
among patients with stable COPD across Europe
and within individual European countries.
METHODS
Survey Design and Study Population
The Respiratory Disease-Specific Programme
(DSP; Adelphi Real World) is a survey which
collects key health outcomes information from
patients diagnosed with COPD routinely
consulting with their treating physicians. The
full methodology of the DSP has been described
previously [10].
Briefly, the DSP involves two key phases.
First, physicians are randomly selected by
members of a local research agency in each
country from public lists of healthcare
professionals practicing in primary care or
respiratory specialty as appropriate. These
physicians are representative of the national
population of physicians in terms of the
physician’s age, gender, and volume of
activity, and are selected based on the quotas
set by specialty type, geographical location, and
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number of patients with COPD currently being
treated by them. For this study, data were
combined from three separate Respiratory DSP
surveys (2010, 2011, and 2012) conducted in
five European countries: France, Germany, Italy,
Spain, and the UK. Each survey was
administered to approximately 500 physicians
[50 primary care physicians (PCPs) and 50
pulmonologists per country].
The second phase involved physicians
completing a standardized record form on the
next six consentingpatientsdiagnosedwithCOPD
visiting their practice. Patients were selected by
physiciansbasedonconsecutivesamplingmeeting
the inclusion criteria of more than 40 years of age
with history of smoking and diagnosis of airflow
obstruction (COPD, emphysema, and/or chronic
bronchitis) irrespective of their reason for
physician visit such as repeat prescription,
routine review, or an unscheduled consultation.
The physician-completed record forms were
completed only for the patients personally seen
by thephysicianeitherduringor immediately after
the consultation by referring to patient records if
needed. The physician-completed record form
collected information on patient demographics,
diagnostic history, and resource use in the past
12 months, current symptomatology and its
impact on lifestyle, current and past treatments,
treatment adherence, comorbidities [11], and
inhaler preference. Of these, data on resource use
in the previous 12 months and the treatments
patients were prescribed at the time of the survey
were used in the present analysis.
Patients for whom a record form had been
completed were then asked to complete a
separate patient self-completion questionnaire
by their physicians in clinic immediately after
the physician visit. Representatives of the data
collection agency ensured that patients
completed their questionnaire without
consulting the doctor, nursing staff, or any
other individual. Patients completed
information on their COPD history, current
symptomatology and its impact on general and
COPD-specific health status, current treatments,
and attitude towards COPD and its treatment.
They also provided information on their health
status at the time of the survey using a series of
validated patient-reported outcome tools. This
included disability due to dyspnoea captured
using the modified Medical Research Council
(mMRC) scale [12], COPD-related health status
using the COPD Assessment Test (CAT) [13],
general health status using the EuroQol
questionnaire (3 levels; EQ-5D-3L) [14], sleep
quality based on the Jenkins Sleep Evaluation
Questionnaire (JSEQ) [15], and medication
adherence using the Morisky Medication
Adherence Scale (MMAS) [16].
Patient Inclusion Criteria
All patients included in this analysis were
40 years or older with a physician-confirmed
diagnosis of airflow obstruction (COPD,
emphysema, and/or chronic bronchitis). The
patients were also required to have received at
least one short- or long-acting COPD-specific
treatment in the previous 12 months and were
required to have a completed response to the
mMRC scale question from the
patient-completed questionnaire.
The survey was conducted as a market
research survey adhering to the ICC/ESOMAR
international code on market and social
research [17] and, therefore, ethical approval
was not sought. Our study was a retrospective
analysis of secondary data. Prior to volunteering
to complete a questionnaire patients were asked
to provide informed consent. The survey
instructions described the purpose of the
survey, why the respondent had been selected,
and who might have access to the aggregated
and anonymized dataset compiled.
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Study Outcomes and Their Derivation
Patients were stratified by their level of
dyspnoea at the time of the survey as
no-to-mild (mMRC \2) or moderate-to-severe
(mMRC C2) dyspnoea [1]. For each of these
strata, patients’ current humanistic burden was
captured using CAT, JSEQ, and EQ-5D-3L.
Utilities were calculated using country-specific
valuation sets of EQ-5D-3L. Utilities were
defined as cardinal values that reflect an
individual’s preferences for different health
outcomes [18]. Thus, EQ-5D-3L utilities in
each country represents preferences of general
public for different health outcomes. The
resource use over the previous 12 months was
estimated using data collected in the
physician-completed patient form. It included
primary and secondary care consultations,
moderate and severe exacerbations, visits to
emergency departments, COPD- and
non-COPD-related hospital stay, as well as
COPD-related medications. Mean estimates for
each resource use were derived for each country
separately and were then converted to costs
using appropriate unit cost for each event (see
Table S1 in the supplementary material).
The unit costs were obtained from the
literature or from a local expert specializing in
health economics [19–32]. If multiple costs were
available, the lowest cost was used as a
conservative estimate. Exacerbation costs were
calculated by combining the cost of treating a
moderate exacerbation with the cost of
prednisolone (40 mg once daily) treatment for
5 days if treated with an oral corticosteroid and/
or the cost of co-amoxiclav treatment (875 mg/
125 mg twice daily) for seven days if treated with
an antibiotic. Country-specific unit costs for
each class of COPD treatment were generated by
averaging the unit costs of the top five (or less)
selling products (in units) within that class for
each country. The total medication cost in a
therapy class was then estimated by multiplying
the number of prescriptions in the last
12 months for that class (currently or
previously received) by the unit cost estimated
based on sales. Missing prescription data were
imputed per country based on the average
number of prescriptions per week for that class.
Data Analysis
To report the burden of dyspnoea at the
European level, patients across individual
countries (France, Germany, Italy, Spain, and
the UK) were pooled to form a single cohort.
Further, the pooled cohort was weighted to
ensure that the sample was more representative
of the patient population. Weighting was based
on an inverse probability of the patients’
12-month consultation rate. For patients with
less than 12 months of consultation history,
this weight was imputed based on their
available consultations and the length of time
the patient has been managed by the physician.
Weightings were not applied to multivariate
analyses.
Patients were described using demographic
and healthcare utilization descriptors by their
level of dyspnoea as no-to-mild (mMRC\2) and
moderate-to-severe (mMRC C2). For each of
these strata, the humanistic burden at the time
of the survey was estimated using CAT, JSEQ,
and EQ-5D-3L. The economic burden based on
physician-reported HCRU also was estimated for
the two dyspnoea-based cohorts. Statistical
differences in humanistic and economic
burden between groups (mMRC \2 vs.
mMRC C2) were assessed using appropriate
weighted regression models, whereby the type
of regression model used depended on the type
or distribution of the outcome variable. A
significance level of 0.05 was used.
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Finally, the two cohorts (mMRC \2 vs.
mMRC C2) were matched using propensity
score matching techniques [33]. Patients with
moderate-to-severe dyspnoea were matched to a
cohort of patients with no-to-mild dyspnoea
with replacement to produce closely matched
profiles [34, 35]. Covariates included in the
matching were age, gender, smoking status,
time since diagnosis, use of inhaled
corticosteroid (ICS)-containing regimens
including triple therapy, exacerbation history,
number of concomitant conditions, and
presence of severe cardiovascular comorbidity
(Table 1). Propensity scores were generated
using logistic regression models. Standardized
mean differences (SMDs) were used to assess
covariate balance once the matching was
complete. An SMD between -10% and 10%
(not inclusive) indicates adequate balance was
achieved for that particular covariate [34]. To
compare the total annual COPD management
costs across two subgroups post-matching, the
Abadie–Imbens (AI) standard error (SE) was
estimated and the corresponding test statistic
and P value were calculated [36, 37]. The effect
of unobserved confounders on the P value was
assessed using Rosenbaum sensitivity analyses
[38]. In addition to the total cohort, this
propensity matching analysis was also
conducted in sub-cohorts of patients treated
with mono-bronchodilators, ICS/long-acting
b-agonist (LABA) fixed-dose combinations, and
triple therapy [long-acting muscarinic
antagonists (LAMA) ? ICS ? LABA or
LAMA ? ICS/LABA]. Analyses were conducted
using Stata v13.0 (StataCorp LP, College Station,
TX, USA) and R v3.0 (R Foundation for
Statistical Computing, Vienna, Austria).
Table 1 Patient disposition and demographic characteristics











Age in years, mean (SD)b 62.8 (9.9) 68.4 (9.2) 66.9 67.5 6.3
Gender, male 914 (70.9) 849 (71.7) 566 (74.3) 543 (71.3) -6.7
Time since diagnosis in months, mean (SD)b 67.3 (52.3) 92.2 (75.7) 89.1 90.8 2.3
Ex-smokersc 832 (64.4) 835 (73.7) 531 (69.7) 530 (69.6) -0.3
Currently on ICS treatmentb 750 (51.5) 828 (69.9) 542 (71.1) 534 (70.1) -2.3
Triple therapyb 374 (26.6) 567 (49.0) 338 (44.4) 357 (46.9) 5.0
2? exacerbations, prior yearb 272 (16.9) 576 (44.3) 382 (50.1) 386 (50.7) 1.0
Number of comorbidities, mean (SD)b 0.8 (1.0) 1.3 (1.4) 1.3 1.3 3.2
Serious CV comorbidityb 302 (22.1) 550 (48.2) 351 (46.1) 352 (46.2) 0.3
Results are presented as n (%) unless otherwise stated
Results for all patients are based on weighted analyses and those for propensity-matched cohort were based on unweighted
data
CV cardiovascular, ICS inhaled corticosteroids, mMRC Modiﬁed Medical Research Council dyspnoea scale, SD standard
deviation, SMD standardized mean difference
a Consists of 400 unique patients
b P\0.0001
c P = 0.0002
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RESULTS
A total of 2531 patients with COPD across five
European countries (France, Germany, Italy
Spain, and the UK) were included in this
study. The mean age of this cohort was
65.4 years and 28.7% were female. The mean
time since COPD diagnosis was 6.6 years and
approximately a third (31.2%) were continuing
smokers. Most patients (60.2%) received an
ICS-containing treatment with 37.2% on triple
therapy (ICS/LABA ? LAMA). The mean
number of concomitant conditions for this
cohort was 1.1 (standard deviation: 1.2) with
approximately a third (34.5%) suffering with
serious cardiovascular comorbidity.
Prevalence of Dyspnoea
Nearly half of the patients (47.3%) reported a
moderate-to-severe level of dyspnoea
(mMRC C2). The frequency of dyspnoea
ranged from 39.5% in France to 60.2% in the
UK (Fig. 1). This was validated using a sample of
respondents, 40 years or older and receiving
respiratory medications, collected as part of
Health Survey of England [39]. The analysis
showed that 56% of respondents indicated that
their condition affects their stamina, breathing,
or fatigue. Patients with dyspnoea were older,
had a longer duration of diagnosed COPD, and
more comorbidities in the combined cohort
(Table 1). A higher proportion of patients with
dyspnoea were ex-smokers, currently received
ICS-containing medications including triple
therapy and suffered from a serious
cardiovascular condition.
Association of Dyspnoea Level
with Health Status
Moderate-to-severe dyspnoea was significantly
associated with poorer health status and sleep
quality. These patients had a higher mean CAT
score of 25.1 (vs. 16.2 for patients with
mMRC\2; P\0.0001) and a mean JSEQ
score of 7.1 (vs. 3.8 for patients with
mMRC\2; P\0.0001; Fig. 2). Patients with
Fig. 1 Prevalence of dyspnoea among patients diagnosed
with chronic obstructive pulmonary disease in the
European countries studied. Percentages are based on
weighted data. EU5: France, Germany, Italy, Spain, and
the UK. mMRC Modiﬁed Medical Research Council
dyspnoea scale
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moderate-to-severe dyspnoea also had a
significantly lower utility score of 0.66
compared to patients with mMRC\2 (0.88;
P\0.0001). These observations were
consistent across all countries surveyed (see
Table S3 in the supplementary material).
Association of Dyspnoea Level with HCRU
Among the moderate-to-severe dyspnoeic
patients, 597 (50.6%) had at least one
moderate exacerbation and 389 (34.7%) had at
least one severe exacerbation in the previous
12 months. The corresponding proportions
for patients with no-to-mild dyspnoea were
30.0% and 9.5%, respectively. In addition,
higher proportions of patients in the
moderate-to-severe dyspnoeic group had at
least one emergency department visit leading
to hospitalization (26.1% vs. 5.8%; P\0.0001)
or not leading to hospitalization (14.7% vs.
3.9%; P\0.0001) compared to patients with
low dyspnoea. The exacerbation rates among
these patients are displayed in Fig. 3.
Similar proportions of patients in both
groups (mMRC C2 vs. mMRC\2) had at least
one PCP consultation (84.6% vs. 85.7%;
P = 0.5898) but higher proportions of
moderate-to-severe dyspnoeic patients had at
least one specialist consultation (90.3% vs.
78.0%; P\0.0001). The annual rate of
physician consultation was higher among
patients with moderate-to-severe dyspnoea,
both for primary and secondary care
consultations (P\0.0001 for both; Fig. 4).
Moderate-to-severe dyspnoeic patients also had
higher proportions of other HCRU, notably
pulmonary rehabilitation, long-term oxygen
therapy, and need for professional care (all
P\0.0001; Table 2).
Fig. 2 Sleep and health status among patients with
no-to-mild and moderate-to-severe dyspnoea at the time
of survey. Values are based on weighted data. }P\0.0001.
CAT COPD Assessment Test, COPD chronic obstructive
pulmonary disease, EQ-5D-3L EuroQol Questionnaire (3
levels), JSEQ Jenkins Sleep Evaluation Questionnaire,
mMRC Modiﬁed Medical Research Council dyspnoea
scale
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Association of Dyspnoea Level with COPD
Management Costs
Mean annual COPD management costs among
the total sample irrespective of dyspnoea levels
were €2552 [95% confidence interval (CI):
€2267, €2838]. More than half the costs were
related to exacerbations and hospitalizations
(€1569; 95% CI: €1354, €1784) with the
remaining distributed between medication
costs (€409; 95% CI: €389, €429), consultation
costs (€301 (95% CI: €282, €320), and other
costs (€258 (95% CI: €152, €364).
In the full cohort, propensity matching on
the baseline demographics and clinical
parameters other than mMRC scores resulted
in 762 patients with mMRC C2 and 762
matched patient profiles (400 unique patients)
Fig. 3 Exacerbation rates in the previous year among
unmatched no-to-mild and moderate-to-severe dyspnoea
patients diagnosed with chronic obstructive pulmonary
disease in the European countries studied. Rates based on
weighted data. }P\0.0001; §P = 0.0114. A&E Accident
and emergency, OCS oral corticosteroids, mMRC
Modiﬁed Medical Research Council dyspnoea scale
Fig. 4 Physician consultation rates in the previous year
among unmatched no-to-mild and moderate-to-severe
dyspnoea patients diagnosed with chronic obstructive
pulmonary disease in the European countries studied.
Rates based on weighted data. }P\0.0001. mMRC
Modiﬁed Medical Research Council dyspnoea scale, PCP
primary care physician
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from a cohort of 919 available patients with
mMRC\2. All covariates were adequately
balanced post-matching (Table 1). In this
propensity-matched cohort, the total annual
COPD management cost was more than twofold
higher among patients with moderate-to-severe
dyspnoea compared to patients with no-to-mild
dyspnoea (€4372 vs. €2031; P\0.0001). The
sensitivity analysis produced a C of 2.3, which
indicates the result is moderately insensitive to
unobserved confounding factors. Although no
statistical comparison was performed on
individual cost components, patients with
moderate-to-severe dyspnoea also showed
higher costs of exacerbations and
hospitalizations (€2898 vs. €1013),
consultations (€432 vs. €306), and other costs
(€556 vs. €235). Medication costs in both groups
were similar (€486 vs. €478). In the
propensity-matched analyses of medication
subgroups, the mean annual COPD
management costs were higher in
moderate-to-severe dyspnoeic patients
compared to no-to-mild dyspnoeic patients in
the mono-bronchodilator subgroup (€1945 vs.
€910; P = 0.0112), ICS/LABA fixed-dose
combination subgroup (€3649 vs. €633;
P = 0.0014) and triple therapy subgroup
(€5766 vs. €2544; P\0.0001; Fig. 5). All
covariates were adequately balanced in the
subgroup analysis, except for time since
diagnosis in the triple therapy subgroup
(SMD = 13.6%).
DISCUSSION
This study estimated the prevalence of
dyspnoea among patients actively consulting
due to their COPD, and its association with
health status and costs in five European
countries. Results showed that across all
countries nearly half of the patients diagnosed
with COPD suffered from moderate-to-severe
dyspnoea. The moderate-to-severe dyspnoeic
patients had worse general and COPD-related
health status and impaired sleep compared to
Table 2 Additional resource use in the previous 12 months
Resource use, n (%)a mMRC < 2 (n5 1332) mMRC ‡ 2 (n5 1199)
Pulmonary rehabilitationc 104 (8.9) 188 (17.8)
Vaccinations
Inﬂuenzae 743 (53.0) 722 (58.5)
Pneumococcald 511 (39.6) 578 (48.0)
Lung transplantationb 0 (0.0) 1 (0.3)
Lung volume reduction surgery 1 (0.0) 5 (0.3)
Long-term oxygen therapyc 24 (1.8) 139 (11.3)
Professional care givers requiredc 2 (0.1) 50 (4.3)
mMRC Modiﬁed Medical Research Council dyspnoea scale
a n are unweighted data and % are weighted data
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patients with no-to-mild dyspnoea. Dyspnoea is
associated with higher HCRU and costs in most
countries. The propensity-matched cohort
analysis showed that patient-reported
dyspnoea had a more than twofold increase in
total costs in the previous year and may,
therefore, remain at potential risk of increased
future costs given the chronicity and
progressive nature of COPD. As these findings
remained after matching for baseline
characteristics in patients with COPD
irrespective of their COPD treatment including
severity and cardiovascular comorbidity, this
suggests that identification and better
management of dyspnoeic patients with
pharmacological and non-pharmacological
interventions may improve their health status
and potentially help local health economy in
controlling COPD management costs.
Several studies have shown the level of
dyspnoea has a significant impact on health
status of patients with COPD. A study
conducted by Punekar and colleagues [40]
using data from the respiratory DSP conducted
in 2007 found EQ-5D-3L scores ranging from
0.88 [Medical Research Council (MRC)
scale = 0] to 0.17 (MRC = 4) in a PCP cohort,
and from 0.88 to 0.29 in a respiratory specialist
cohort with differing levels of dyspnoea across
the same five European countries reported here.
The healthcare utilities in our study for the
no-to-mild dyspnoeic patient group (mMRC\2)
were identical at 0.88 but were substantially
higher for patients with moderate-to-severe
dyspnoea (mMRC C2; 0.17/0.29 vs. 0.67). This
may be attributable to differing definitions of
moderate-to-severe dyspnoea in our study
(mMRC C2) compared to the Punekar study
(mMRC = 4). Another study by Mullerova and
colleagues [8] found that the presence of even
mild dyspnoea (as compared to no dyspnoea) to
be associated with more disease burden and
higher frequency of comorbidities and a study
by Kessler and others [4] found dyspnoea
Fig. 5 Chronic obstructive pulmonary disease-related
annual total costs in the propensity-matched patient
cohorts with no-to-mild and moderate-to-severe dyspnoea
and subgroups segmented by treatment type. }P\0.0001;
§P = 0.0112; ¥P = 0.0014. *Propensity-matched sample
where n for ‘mMRC\2’ = n for ‘mMRC C2’ ICS inhaled
corticosteroid, LABA long-acting b-agonist, mMRC
Modiﬁed Medical Research Council dyspnoea scale
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having significant impact on daily activities.
Similarly, other studies have found dyspnoea to
have a negative impact on CAT, SGRQ, and the
12-Item Short Form Health Survey (SF-12)
physical component [41–43].
The Confronting COPD survey estimated the
burden of COPD on patients globally [44]. The
economic sub-analysis of confronting COPD
survey indicated that costs ranged from €590
(direct cost: €395; indirect cost: €195) in
patients with mild dyspnoea to €4670 (direct
cost: €3036; indirect cost: €1634) in patients
with severe dyspnoea in the UK [44]. The
corresponding costs ranged from €441 in
patients with mild dyspnoea to €6365 in
patients with severe dyspnoea in Italy [45]. In
contrast, a retrospective database analysis of
Clinical Practice Research Database conducted
by Punekar and colleagues [46] estimated the
costs in the range of £1597–3579 among
patients with increasing levels of dyspnoea in
the UK. The estimated costs in our study were
comparable.
Our study has potential limitations. The
sample collected was a convenience sample of
consecutive eligible patients with COPD who
actively consulted their physician; therefore, it
may not fully represent the broad population of
patients with COPD in the community in each
country who may present less frequently to
healthcare providers. However, the
methodology does aim to remove any possible
selection bias by removing any direct influence
from the physician on the selection process.
Moreover, the prevalence of dyspnoea and
distribution of airflow limitation severity was
similar to those observed in other studies
conducted in general practice [43]. While
minimal exclusion criteria governed the
selection of physicians (mainly relating to the
necessity of participating physicians to see a
minimum volume of patients and be actively
involved in patient management and treatment
decisions), physician inclusion was likely
influenced by their willingness to take part,
and practical considerations of geographical
location. These results were weighted to make
them more generalizable to the COPD
population in the specific country in which
data were collected. In some instances, this
resulted in negative CIs on costs due to an
assumption of normality in calculating the
95% CIs for right-skewed cost data.
The association of moderate-to-severe
dyspnoea versus no-to-mild dyspnoea with
HCRU has the limitation that the exposure
(evaluation of dyspnoea via mMRC) comes after
the outcomes being measured in the prior
12 months. However, our findings are in good
agreement with prospective COPD populations
studies in patients inGlobal initiative for chronic
Obstructive Lung Disease (GOLD) groups A–D,
which have shown moderate-to-severe
breathlessness at entry is strongly associated
with an increase in COPD- and
non-COPD-related hospitalizations and future
mortality [47, 48]. Moreover, mMRC grading
captured prospectively or retrospectively at a
point in time appears insensitive to short-term
changes even when initiating or removing
treatment and it is uncommon for population
scores to alter by a fraction of a grade or
individuals to improve or deteriorate by an
entire grade in this period of follow-up [49, 50].
CONCLUSIONS
Dyspnoea is a highly prevalent symptom
among patients with COPD recruited
across multiple European countries.
Moderate-to-severe dyspnoea presents
significant humanistic burden on patients and
is directly or indirectly associated with a high
economic impact on the healthcare system.
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